# US 11,027,010 B2 · Reduction of in vitro genotoxicity of pollen extracts by removal of flavonoids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,027,010 B2
- Document ID: US11027010B2
- Status: Granted
- Kind: B2
- Application number: 15/416,195
- Filed: 2017-01-26
- Published: 2017-08-10
- Granted: 2021-06-08
- Earliest claimed: 2009-06-05
- Assignees: Stallergenes
- Applicants: Stallergenes
- Inventors: Philippe Moingeon; Thierry Batard; Bertrand Villet
- Web page: https://patentgrep.com/patent/US11027010B2

## CPC

- A61K 39/36: from pollen
- A61K 36/00: Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines {(antigens from pollen A61K39/36)}
- A61P 37/02: Immunomodulators
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to grass pollen extracts containing reduced amount of flavonoid glycosides in order to minimize the risks of genotoxicity of the grass pollen extracts. The invention also relates to a method of preparing grass pollen extracts containing reduced amount of flavonoid glycosides by ultrafiltration. Flavonoid glycosides are naturally present in grass pollen extracts and they have been identified as being responsible for the formation of flavonoid aglycones, which are genotoxic in vitro, under the influence of enzymes contained in the grass pollen extracts.

## Claims

### Claim 1

A pharmaceutical composition comprising a purified pollen extract containing pollen allergen comprising a mixture of cocksfoot, meadow grass, rye-grass, sweet vernal-grass and timothy grass extracts, wherein the composition contains an amount of each flavonoid that is less than 0.002 g per 100 g of pollen derived fraction, as expressed in aglycone equivalent, and a pharmaceutically acceptable carrier comprising a vaccination adjuvant selected from the group consisting of heat-labile enterotoxin, choleratoxin, cholera toxin B subunit, polymerized liposomes, and mutant toxins.

### Claim 2 (depends on 1)

A method of treating pollen allergy comprising administering to a subject in need thereof pharmaceutical a composition according to claim 1.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein each flavonoid is contained in an amount which is less than 0.001 g per 100 g of pollen derived fraction, as expressed in aglycone equivalent.

### Claim 4 (depends on 2)

The method of treating pollen allergy according to claim 2, wherein the pharmaceutical composition contains an amount of each flavonoid that is less than 0.001 g per 100 g of pollen derived fraction, as expressed in aglycone equivalent.